OCT in Retinal Disease

For decades, fluorescein angiography (FA) was the gold standard for imaging retinal vascular diseases, but it was invasive, time-consuming, and provided only two-dimensional vascular information without cross-sectional structural detail. Optical coherence tomography (OCT) was first demonstrated in vivo in 1993 by Huang et al. at MIT, using low-coherence interferometry to generate cross-sectional images of the retina with 10-micron resolution. Early time-domain OCT (TD-OCT) systems such as the Zeiss Stratus OCT, introduced commercially in 2002, provided the first practical tool for quantitative measurement of retinal thickness and macular morphology. The ability to visualize individual retinal layers non-invasively was immediately recognized as transformative for understanding diseases like diabetic macular edema and age-related macular degeneration.

Spectral-domain OCT (SD-OCT), introduced commercially around 2006, represented a quantum leap with 100x faster scanning speeds and 5-micron axial resolution, enabling three-dimensional volumetric imaging of the retina. SD-OCT became integral to the anti-VEGF treatment paradigm for wet AMD and diabetic macular edema, with clinical trials including CATT and Protocol T using OCT-defined endpoints to guide treatment decisions. The technology transformed glaucoma management by enabling precise measurement of retinal nerve fiber layer and ganglion cell complex thickness for early detection of structural damage before visual field loss. By 2010, OCT had become the most frequently performed ophthalmic imaging test, fundamentally changing how retinal disease is diagnosed and monitored.

OCT angiography (OCTA), available commercially from 2014, provided non-invasive visualization of retinal and choroidal vasculature without dye injection, partially replacing fluorescein angiography for many indications. Swept-source OCT (SS-OCT) pushed imaging deeper through the choroid with 1050nm wavelength sources and even faster scan rates. AI-enhanced OCT analysis emerged as a major research focus, with DeepMind/Moorfields demonstrating in 2018 that deep learning could diagnose over 50 retinal conditions from OCT scans with accuracy matching expert specialists. Retinal layer biomarkers—such as ellipsoid zone integrity, hyperreflective foci, and subretinal fluid volume—became recognized as predictive markers for treatment response and disease progression.

OCT is now embedded in virtually all ophthalmic clinical practice guidelines as an essential diagnostic and monitoring tool. The AAO Preferred Practice Patterns for AMD, glaucoma, and diabetic eye disease all incorporate OCT-guided treatment algorithms. The International Council of Ophthalmology recommends OCT as the primary imaging modality for monitoring anti-VEGF therapy. NICE guidelines incorporate OCT central subfield thickness as a treatment initiation and retreatment criterion for macular diseases. Guidelines increasingly recognize OCT biomarkers as valid surrogate endpoints in clinical trials.

OCT technology continues to evolve rapidly. Home OCT monitoring devices (Notal Vision, ForeseeHome OCT) are being developed to enable patients with wet AMD to self-monitor between clinic visits, potentially detecting disease reactivation earlier. Visible-light OCT promises even higher resolution for superficial retinal layers. AI-powered OCT analysis is moving toward predicting disease conversion (dry-to-wet AMD, diabetic retinopathy progression) before clinical signs are apparent, enabling preventive treatment. Widefield OCT systems can now image the entire posterior pole in a single scan. The integration of OCT with other imaging modalities and electronic health records through AI platforms is creating a comprehensive retinal digital twin for each patient.